KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.95

Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma.

Yang Zhang, Bin Qian, Qingping Song, Junjie Ma, Hang Cao, Chaoqiang Deng, Shengping Wang, Ting Ye, Jiaqing Xiang, Yawei Zhang, Yihua Sun, Yueren Yan, Shanbo Zheng, Haoxuan Wu, Qingyuan Huang, Hong Hu, Yuan Li, Fangqiu Fu, Haiquan Chen

J Clin Oncol 43(28) 3081-3089

PMID40690727
PMCIDPMC12456192
DOI10.1200/JCO-25-00610
发表日期2025-07-21
入排依据:The study is an oncology Phase III randomized trial in humans with a primary time-to-event endpoint (DFS) and reports original results. However, it is excluded because it does not involve a drug-containing intervention, comparing only surgical procedures.
摘要

摘要

PURPOSE: Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non-small cell lung cancer. We aimed to investigate whether no mediastinal LND was noninferior to systematic LND in patients with ground glass opacity (GGO)-dominant invasive lung adenocarcinoma. METHODS: We conducted a multicenter, open-label, phase III, noninferiority randomized controlled trial comparing systematic mediastinal LND versus no mediastinal LND in patients with GGO-dominant invasive lung adenocarcinoma, who were predicted to have no lymph node metastasis on the basis of criteria established in our previous trial. The primary end point was 3-year disease-free survival. An interim analysis was planned upon enrollment of 300 patients, with predefined termination criteria if no mediastinal lymph node metastasis is detected and life-threatening complications occur in the systematic LND arm. This trial is registered on ClinicalTrials.gov (ECTOP-1009, identifier: NCT04527419). RESULTS: Interim analysis of 302 patients revealed no lymph node metastasis in either study arm. The no LND arm had significantly reduced surgery duration (mean, 74 minutes v 109 minutes; P < .001), blood loss (mean, 44 mL v 82 mL; P = .033), and postoperative hospital stay (mean, 3.9 days v 4.5 days; P = .002). Complications observed in the systematic LND arm included chylothorax in one patient (0.7%) and intraoperative massive bleeding because of superior vena cava injury in one patient (0.7%). No lymphadenectomy-related complications occurred in the no LND arm. CONCLUSION: On the basis of interim findings and the principle of nonmaleficence, the trial should be terminated. Systematic mediastinal LND should no longer be recommended for patients with GGO-dominant lung adenocarcinoma.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. Kaplan-Meier curves of (A) disease-free survival and (B) overall survival, stratified by mediastinal LND or not. LND, lymph node dissection.

A

disease-free survival

FIG 2. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

overall survival

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Trial profile. AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; LND, lymph node dissection; MIA, minimally invasive adenocarcinoma.
非 KM Figure